Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 3/20 | 0.59 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.56 |
| ▸ | PNMT | P11086 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | BACE1 | P56817 | 2/20 | 0.55 |
| ▸ | ACP3 | P15309 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL118305 | 0.83 | PNMT (0.52) | BCHESLC16A3PNMT | |
| SCHEMBL118320 | 0.83 | PNMT (0.52) | BCHESLC16A3PNMT | |
| SCHEMBL115977 | 0.83 | PRMT5 (0.48) | LMNA | |
| SCHEMBL10070266 | 0.82 | PNMT (0.51) | BCHEPNMT | |
| SCHEMBL10070265 | 0.82 | PNMT (0.51) | BCHEPNMT | |
| SCHEMBL117129 | 0.81 | BCHE (0.49) | BCHEPNMTBACE1 | |
| SCHEMBL115946 | 0.81 | BCHE (0.49) | BCHEPNMTBACE1 | |
| SCHEMBL27731739 | 0.81 | SLC16A3 (0.60) | SLC16A3LMNAMEN1KMT2A | |
| SCHEMBL2298340 | 0.81 | SLC16A3 (0.60) | SLC16A3LMNAMEN1KMT2A | |
| SCHEMBL2291798 | 0.81 | SLC16A3 (0.60) | SLC16A3LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | BCHE 4506/4885SLC16A3 3951/4885PNMT 2146/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.